{"id":2494,"date":"2018-01-10T19:43:58","date_gmt":"2018-01-10T14:13:58","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2494"},"modified":"2021-07-24T12:56:54","modified_gmt":"2021-07-24T07:26:54","slug":"snippet-3","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/snippet-3","title":{"rendered":"Snippet"},"content":{"rendered":"

Gene therapy is back into play after a decade-long failed deliveries. 2017 was a golden year in gene therapy arena, various companies are aggressively developing gene therapy based treatments targeting life-threatening indications. Spark therapeutics<\/strong> got USFDA approval for the first-ever gene therapy based blindness treatment Luxturna<\/strong>. The therapy will help patients with a faulty gene in DNA i.e. RPE65 gene. The company will insert a functional RPE65 gene into the patients DNA to replace the defective gene resulting in vision restoration. It\u2019s a one-time treatment with a hefty price tag of around USD 1 million making it a long shot for the patients. Luxturna got the approval last month and according to the spark therapeutics the treatment will cost around USD 425000<\/strong> per injection excluding the cost of operation which will further add around USD 4000 \u2013 USD 5000<\/strong> to the same. For justifying the hefty price tag spark therapeutics stated that \u201cthe cost for a lifetime of blindness including lost earnings and caregiver wages can easily exceed $1 million\u201d.\u00a0 Being a breakthrough treatment based on gene therapy Luxturna surely is a hot topic in the pharmaceutical industry with experts analyzing the potential of the therapy and price associated with it.<\/p>\n","protected":false},"excerpt":{"rendered":"

Gene therapy is back into play after a decade-long failed deliveries. 2017 was a golden year in gene therapy arena, various companies are aggressively developing gene therapy based treatments targeting life-threatening indications. Spark therapeutics got USFDA approval for the first-ever gene therapy based blindness treatment Luxturna. The therapy will help patients with a faulty gene […]<\/p>\n","protected":false},"author":1,"featured_media":2495,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[1281,1168,134,1155,204,704,258,1283,1282,1230,543,595],"industry":[17225],"therapeutic_areas":[17235,17244],"class_list":["post-2494","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-blindness-gene-therapy","tag-business-consultancy","tag-business-consultant","tag-consultancy","tag-delveinsight","tag-fda","tag-gene-therapy","tag-luxturna","tag-million-dollar-gene-therapy","tag-pharma-consultancy","tag-spark-therapeutics","tag-usfda","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"\nSpark therapeutics got USFDA approval for gene therapy Luxturna.<\/title>\n<meta name=\"description\" content=\"Gene therapy is back into play after a decade-long failed deliveries. 2017 was a golden year in gene therapy arena\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/snippet-3\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spark therapeutics got USFDA approval for gene therapy Luxturna.\" \/>\n<meta property=\"og:description\" content=\"Gene therapy is back into play after a decade-long failed deliveries. 2017 was a golden year in gene therapy arena\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/snippet-3\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-10T14:13:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021700\/image-20151106-16253-1rzjd0s.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1356\" \/>\n\t<meta property=\"og:image:height\" content=\"668\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Spark therapeutics got USFDA approval for gene therapy Luxturna.","description":"Gene therapy is back into play after a decade-long failed deliveries. 2017 was a golden year in gene therapy arena","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/snippet-3","og_locale":"en_US","og_type":"article","og_title":"Spark therapeutics got USFDA approval for gene therapy Luxturna.","og_description":"Gene therapy is back into play after a decade-long failed deliveries. 2017 was a golden year in gene therapy arena","og_url":"https:\/\/www.delveinsight.com\/blog\/snippet-3","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-01-10T14:13:58+00:00","article_modified_time":"2021-07-24T07:26:54+00:00","og_image":[{"width":1356,"height":668,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021700\/image-20151106-16253-1rzjd0s.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-3","url":"https:\/\/www.delveinsight.com\/blog\/snippet-3","name":"Spark therapeutics got USFDA approval for gene therapy Luxturna.","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-3#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-3#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021700\/image-20151106-16253-1rzjd0s.jpg","datePublished":"2018-01-10T14:13:58+00:00","dateModified":"2021-07-24T07:26:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Gene therapy is back into play after a decade-long failed deliveries. 2017 was a golden year in gene therapy arena","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/snippet-3"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-3#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021700\/image-20151106-16253-1rzjd0s.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021700\/image-20151106-16253-1rzjd0s.jpg","width":1356,"height":668},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021700\/image-20151106-16253-1rzjd0s-300x148.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">blindness gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">business consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Luxturna<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">million dollar gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Spark therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">USFDA<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">blindness gene therapy<\/span>","<span class=\"advgb-post-tax-term\">business consultancy<\/span>","<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Luxturna<\/span>","<span class=\"advgb-post-tax-term\">million dollar gene therapy<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">Spark therapeutics<\/span>","<span class=\"advgb-post-tax-term\">USFDA<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 10, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 10, 2018 7:43 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2494"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2494\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2495"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2494"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2494"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}